Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis

Manuel Carção(Hospital for Sick Children), C. Escuriola‐Ettingshausen(Haemophilia Foundation Australia), Elena Santagostino(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Thierry Lambert(Bicêtre Hospital), Cindy Leissinger(National Institutes of Health)
Haemophilia
July 10, 2018
10.1111/hae.13558
Cited by 8

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587